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1. Introduction  
Exclusive breastfeeding for the first 4–6 months of life is endorsed for primary 
prevention of allergic diseases in children on the basis of epidemiological findings 
and expert opinion [1]. The protective effect of breast milk (BM) against atopic 
dermatitis (AD) was shown by a meta-analysis in 2001 [2]. However, a later meta-
analysis in 2009 indicated no relation between feeding methods and AD [3]. 
Furthermore, a recent large-scale epidemiological study in Japan showed an apparent 
risk of developing AD due to breastfeeding [4]. One of the reasons for these 
differences in results with time may be changes in environmental factors in modern 
society, including immune modulators in breast milk [5].  
Human BM contains a number of specific and nonspecific anti-inflammatory 
substances. Soluble CD14 (sCD14) is one of the BM components that aid neonatal 
gut function and development [6–8], modulates immune function, and regulates 
inflammation [9–12]. It acts as a co-receptor along with toll-like receptor 4 (TLR4) 
and MD-2 in the detection of LPS and binds to LPS more efficiently in the presence 
of lipopolysaccharide-binding protein [13–15]. An interaction between polymorphism 
in the CD14 gene and endotoxin exposure may play a role in the development of 
allergies [16]. 
Consensus on the involvement of human BM sCD14 in the development of atopic 
manifestations in childhood has not been established. Several cohort studies reported 
that lower sCD14 in BM were associated with allergen sensitization or allergic 
symptoms [17–21]. By contrast, Savilahi et al. documented that higher sCD14 levels 
in BM 3 months postpartum were associated with IgE-mediated allergic disorders by 
the age of 5 years [22]. Other studies found sCD14 levels either in colostrum or 
mature milk were not associated with subsequent development of eczema or atopic 
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sensitization during early life [23–26]. The substantial variations in study protocols, 
such as time of outcome measurement, selection of subjects, change in other 
immunomodulators in BM with time, etc., may contribute to these conflicting results.  
In this study, to understand the involvement of sCD14 in BM in atopic manifestations 
in early infancy, we studied the association of sCD14 levels in colostrum and 1-month 
BM, with the development of AD and allergen sensitization at 9 months of age in 
exclusively breastfed or almost exclusively breastfed infants in a birth cohort in 
Japan. 
 
2. Materials and Methods 
2.1. Participants 
The present study used the findings of our previous study (Katsushika study, a 2 × 2 
factorial, randomized, non treatment-controlled trial study to evaluate the prevention 
of AD or food allergy (FA) by use of skincare and synbiotics in infants) (n = 549). 
The study was approved by the Chiba University Ethics Committee (reference no. 
2067) and was registered at the University Hospital Medical Information Network 
(JPRN-UMIN000010838). There was no significant preventive effect of skincare 
and/or synbiotic on the development of AD up to 1 year of age [27] Children who 
were exclusively or almost exclusively breastfed up to four months were studied in 
the present study. Feeding method up to 4 months was determined from a 
questionnaire completed by mothers when infants were 6 months of age. 
2.2. Definition of Maternal Allergic History 
A positive maternal allergic history was defined as, physician-diagnosed asthma, AD, 
rhinoconjunctivitis, or FA in the mother, as declared in a self-reported questionnaire.  
2.3. Definition of Feeding Method 
 5 
Exclusively or almost exclusively breastfed infant was defined as one who had no 
nutrition other than breast milk or mostly breast milk nutrition until 4 months of age. 
2.4. Definition of Infant’s AD and Infant’s Allergic Sensitization 
Infants were examined for AD by a pediatrician at 9 months of age, and the presence 
or absence of AD was determined using guidelines of the Japanese Dermatological 
Association [28]. Specific IgE for hen’s egg white, cow’s milk, house dust mite, and 
cat dander were also measured at 9 months of age by ImmunoCap® system (Phadia 
KK.,Tokyo, Japan). Infants were considered to be sensitized if specific serum IgE 
levels were ≥0.7 kU/L against one or more of the tested foods or inhalant allergens. 
2.5. Colostrum and BM Collection 
BM samples were collected from mothers, 3–5 days postpartum, and 1 month 
postpartum. Each sample was frozen at −80 °C within 12 h after collection. For 
analysis of sCD14 in this study, frozen BM samples were thawed and centrifuged at 
10,000 rpm for 10 min. The cellular debris and fat layer were discarded, and the 
aqueous fraction was centrifuged again at 10,000 rpm for 5 min. The resulting 
aqueous layer was used for analysis. 
2.6. Measurement of sCD14 
The concentration of sCD14 in the aqueous phase of BM samples was measured in 
duplicate using a commercial human sCD14 ELISA kit according to the 
manufacturer’s protocol (Human sCD14 DuoSet ELISA kit, R & D System, 
Minneapolis, MN, USA). Samples were assayed at a dilution of 1:40,000 for 
colostrum, and 1:10,000 for 1-month BM. Recombinant human sCD14 was used as a 
positive control and the reagent diluent buffer provided by the manufacturer was used 
as a negative control. Seven-point standard curves using 1:2 serial dilutions were 
generated in the range of 4000–62.5 pg/mL. sCD14 concentration was determined 
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based on the standard curve generated by PLATEmanager V5 for Sunrise program 
(Wako Pure Chemical Industries, Ltd., Osaka, Japan) using a four-parameter equation 
and results were reported in µg/mL.  
2.7. Statistical Analysis 
Data were analyzed as continuous or dichotomous data (detected or not detected). 
Results for categorical variables, including maternal allergic history, mode of 
delivery, gender, season of birth, and age of mother were compared with the 
outcomes by Chi-square test. Wilcoxon rank sum test or Kruskal–Wallis test for 
nonparametric analysis was used to compare sCD14 concentration in colostrum and 
1-month BM with the outcomes. To assess the possible association between colostral 
sCD14 or 1-month BM sCD14 levels and outcomes, potential confounding factors 
(mode of delivery, maternal allergic history, gender, season of birth, and age of 
mother) were included in a nominal logistic regression model. The dose-dependent 
trend of BM sCD14 levels with respect to the outcomes was analyzed by the 
Cochran–Armitage trend test. A p-value < 0.05 was considered significant. Statistical 
analysis was performed using JMP13 (SAS Institute Inc., Cary, NC, USA). 
 
3. Results 
3.1. BM Samples and sCD14 Concentration 
A total of 258 colostrum samples and 269 1-month BM samples were collected, 
respectively. Two hundred and forty-six of colostrum and 1-month BM were paired 
samples. The characteristics of the samples are summarized in Table 1. There was a 
significant change in sCD14 levels between the two time points; colostrum (median 
20.8 µg/mL, range 2.2–45.9 µg/mL) and 1-month BM (median 7.87 µg/mL, range 
0.88–28.3 µg/mL) (Wilcoxon rank sum test, p < 0.0001) (Figure 1a). We found no 
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significant difference in sCD14 levels in colostrum (p = 0.14, Wilcoxon rank sum 
test) and 1-month BM (p = 0.82, Wilcoxon rank sum test) between mothers with or 
without allergic history (Figure 1b). 
 
Figure 1. (a) Levels of sCD14 in colostrum (n = 258) and in 1-month BM (n = 269). 
There was a significant difference between colostral sCD14 and 1-month BM sCD14 
levels (Wilcoxon rank sum test, p < 0.0001) and (b) Colostral sCD14 and 1-month 
BM sCD14 levels with or without maternal allergic history. In AD or non-AD infants, 
sCD14 levels in BM were not significantly different between mothers with allergic 
history and those without allergic history (Wilcoxon rank sum test, p > 0.05). The 
levels are shown as median with interquartile ranges. 
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Table 1. Characteristics of colostrum and 1-month BM samples. 
 
Characteristics Colostrum 1-Month BM n = 258 * n = 269 * 
Maternal allergic history, n (%)   Yes 123 (48) 125 (46) 
No 135 (52) 144 (54) 
Sex, n (%)   Male 132 (51) 138 (51) 
Female 126 (49) 131 (49) 
Mode of delivery, n (%)   Vaginal delivery 203 (79) 213 (79) 
Caesarian delivery 55 (21) 56 (21) 
Season of birth, n (%)   Spring 82 (32) 83 (31) 
Summer 72 (28) 71 (26) 
Autumn 47 (18) 55 (21) 
Winter 57 (22) 60 (22) 
Age of mother (year), n (%)   ≤25 5 (2) 5 (2) 
>25–35 167 (65) 173 (64) 
>35 86 (33) 91 (34) 
9-month follow-up   Atopic dermatitis, n (%)   Yes 69 (27) 74(27.5) 
No 184 (71) 195 (72.5) 
Lost to follow-up 5 (2) 0 (0) 
Egg white sensitization, n (%)   Yes 121 (47) 127 (47) 
No 135 (52) 142 (53) 
Lost to follow-up 2 (1) 0 (0) 
Cow’s milk sensitization, n (%)   Yes 23 (9) 26 (10) 
No 232 (90) 242 (89) 
Lost to follow-up 3 (1) 1 (1) 
House dust mite sensitization, n (%)   Yes 11 (4) 13 (5) 
No 245 (95) 256 (95) 
Lost to follow-up 2 (1) 0 
Cat sensitization, n (%)   Yes 8 (3) 7 (2) 
No 247 (96) 261 (97) 
Lost to follow-up 3 (1) 1 (1) 
* Two hundred and forty-six of colostrum and 1-month BM were paired samples. 
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3.2. Association between BM sCD14 Levels and AD at 9 Months of Age 
Colostral sCD14 levels were not different between children who developed AD at 9 
months of age and those who did not (p = 0.804) (Table 2). In contrast, 1-month BM 
sCD14 levels in the AD group were significantly lower than those in the non-AD 
group (p = 0.001). This association was confirmed by using logistic regression with 
adjustment for maternal allergic history, gender, mode of delivery, season of birth, 
and age of mother (adjusted p = 0.002). In order to determine the effect size of 1-
month BM sCD14 on the development of AD, we divided 1-month BM sCD14 levels 
into four groups and analyzed by logistic regression with adjustment for the 
confounders, showing that higher levels of 1-month BM sCD14 significantly 
decreased the risk of the development of AD at 9 months (Table 3).  
Table 2. Association of BM sCD14 with atopic dermatitis (AD) at 9 months of age. 
BM sCD14 AD Non-AD p-Value * Adjusted p-Value † 
Colostrum (µg/mL) 20.87 (3.55–45.31) 20.91 (2.2–45.9) 0.804 0.971 
1-month BM (µg/mL) 6.86 (1.1–19.3) 8.53 (0.88–28.26) 0.001 0.002 
Levels are shown as median with interquartile range. * Groups were compared by 
Wilcoxon rank sum test. † Logistic regression analysis adjusted for gender, mode of 
delivery, maternal allergic history, season of birth, and age of mother. 
Table 3. Logistic regression analysis for the effects of 1-month BM sCD14 on AD at 
9 months of age. 
BM sCD14 sCD14 Levels (µg/mL) Adjusted OR (95% CI) p-Value 
Very low 0.88–6.104 1 - 
Low 6.105–7.86 0.78 (0.36–1.68) 0.529 
Middle 7.87–10.10 0.36 (0.15–0.89) 0.028 
High 10.11–28.26 0.38 (0.16–0.89) 0.027 
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Logistic regression analysis adjusted for gender, mode of delivery, maternal allergic 
history, season of birth, and age of mother. OR (95% CI): odds ratio (95% confidence 
interval). 
3.3. Association between BM sCD14 Levels and Sensitization to Allergens at 9 
Months of Age 
We analyzed the association between colostral sCD14 or 1-month BM sCD14 levels, 
and sensitization to egg white (EWS), cow’s milk, house dust mite, and cat dander. 
The level of sCD14 in 1-month BM was significantly lower in the EWS group 
compared to the control group (p = 0.01) (Table 4). However, this association was lost 
after adjustment for other confounding factors (p = 0.871). Since AD had a strong 
effect on sensitization, we stratified subjects based on the presence and absence of 
AD. EWS was significantly decreased by increasing 1-month BM sCD14 levels in 
non-AD infants but not in AD infants (Figure 2) (p = 0.042, Cochran–Armitage trend 
test).  
Table 4. Association of BM sCD14 with sensitization to egg white (EWS) at 9 months 
of age. 
BM sCD14 EWS Non-EWS p-Value * Adjusted p-Value † 
Colostrum (µg/mL) 20.87 (8.82–45.9) 20.78 (2.2–45.7) 0.777 0.871 
1-month BM (µg/mL) 7.26 (1.05–16.71) 8.57 (0.88–28.26) 0.01 0.183 
Levels are shown as median with interquartile range. * Groups were compared by 
Wilcoxon rank sum test. † Logistic regression analysis adjusted for gender, mode of 
delivery, maternal allergic history, season of birth, age of mother, and AD at 9 
months. 
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Figure 2. Dose-dependent trend for sCD14 levels in 1-month BM to EWS at 9 months 
of age in AD (a) and non-AD (b) infants. EWS decreased significantly with 
increasing sCD14 levels in 1-month BM in non-AD infants (Cochran–Armitage trend 
test, p = 0.042). 
4. Discussion 
In the present study, we found that sCD14 levels in 1-month BM were significantly 
lower in children with AD compared to those without AD at 9 months of age who 
were exclusively or almost exclusively breastfed up to 4 months. Our findings are in 
accord with Savilahti and co-workers’ results, which showed that atopic symptoms 
and IgE sensitization at 4 years of age were associated with lower colostral sCD14 
levels [18]. Recently, Hua et al. reported that lower sCD14 levels in the colostrum and 
two-month BM were associated with AD at 2 years of age in children who were born 
to mothers with allergies in univariate analysis. Unfortunately, the association was 
lost while performing a logistic regression analysis. Notably, in our study, the 
association between 1-month BM sCD14 levels and nine-month AD were 
independent of maternal allergic history and gender, which were also associated with 
nine-month AD. In contrast to the present study, Ismail et al. reported that sCD14 
levels in 28-day BM were not associated with the development of eczema or allergen 
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sensitization in infants at 12 months [24]. The reason for the discrepancy is not clear. 
However, there is a possibility that sCD14 in BM was modified since mothers took 
probiotics during pregnancy in their study [19]. In our study, synbiotics were given to 
the babies but not the mothers; thus, this intervention may not have an effect on the 
mother’s status. We included the intervention in logistic regression analysis and the 
results were not changed (data not shown). This analysis of results indicated that there 
was no synergistic effect of the treatments and 1-month BM sCD14 in the 
development of AD at 9 months. One-month BM sCD14 levels were independently 
associated with the outcome. Another reason for this discrepancy might be different 
characteristics of the enrolled subjects. Our study subjects were from an unselected 
population while the aforementioned study recruited high-risk children with a family 
history of allergy. In fact, the prevalence of AD in our study is lower than that in their 
study, and EASI score in children with AD in our study was not high (data not 
shown). 
We found lower 1-month BM sCD14 levels were associated with the development of 
EWS at 9 months of age in non-AD infants. Our results are similar to other studies 
that found an association between BM sCD14 with allergen sensitization in childhood 
[18,22]. However, the effect of sCD14 on allergen sensitization seems to be much 
weaker because its effect is not observed in the presence of AD, which is a strong 
enhancing factor for allergen sensitization.  
Our study has some limitations. The outcomes were set at 9 months of age in this 
study to minimize factors other than breastfeeding. Longer follow-up is necessary to 
determine the long-term effect of sCD14 in BM. Our study did not look at the role of 
sCD14 in BM in the development of AD in the high-risk population, which might be 
important for personalized prevention.  
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In conclusion, we found that low sCD14 levels in 1-month BM were significantly 
associated with the development of AD at 9 months of age and weakly associated 
with sensitization to egg white at 9 months in non-AD infants. The results suggest that 
the sCD14 in BM may be a protective factor for subsequent allergic diseases and/or 
allergen sensitization.  
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